| Exclusion Criteria: | 1) Any significant diseases (other than HL) or clinically significant findings, including psychiatric and behavioral problems, medical history and/or physical examination findings that would preclude the subject from participating in the study.
2) History or clinical evidence of central nervous system (CNS) HL.
3) If patient has received allogeneic BMT, no evidence of active graft-versus-host disease (GVHD), and currently not receiving immunosuppressive therapy.
4) Received growth factor support or transfusions to achieve hematology entry criteria (platelets, hemoglobin, absolute neutrophis count)
5) Major surgery within 4 weeks prior to study entry.
6) Known hypersensitivity to recombinant proteins or any excipient contained in the drug formulation.
7) Known history of another primary malignancy that has not been in remission for at least 5 years. Non-melanoma skin cancer and cervical carcinoma in situ or squamous intraepithelial lesions (e.g., cervical intraepithelial neoplasia [CIN] or prostatic intraepithelial/intraductal neoplasia [PIN]) are allowed.
8) Any serious active viral, bacterial, or systemic fungal infection prior to study enrollment.
9) Known positive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg), or hepatitis C virus (HCV).
10) History of significant chronic or recurrent infections requiring treatment.
11) Receiving systemic steroids exceeding 10 mg prednisone or equivalent, or unstable on steroid medication, during the 3 weeks immediately preceding enrollment.
12) Pregnant or breast-feeding. |